Literature DB >> 14551157

Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization.

Chad Johnson1, Zorina S Galis.   

Abstract

OBJECTIVE: Smooth muscle cells (SMCs) produce both matrix metalloproteinase (MMP)-2 and MMP-9, enzymes with similar in vitro matrix degrading abilities. We compared the specific contributions of these enzymes to SMC-matrix interactions in vitro and in vivo. METHODS AND
RESULTS: Using genetic models of deficiency, we investigated MMP-2 and MMP-9 roles in SMC migration in vivo in the formation of intimal hyperplasia and in vitro. In addition, we investigated potential effects of MMP-2 and MMP-9 genetic deficiency on compaction and assembly of collagen by SMCs.
CONCLUSIONS: MMP-2 and MMP-9 genetic deficiency decreased by 81% and 65%, respectively (P<0.01), SMC invasion in vitro and decreased formation of intimal hyperplasia in vivo (P<0.01). However, we found that MMP-9, but not MMP-2, was necessary for organization of collagen by SMCs. Likewise, we found that MMP-9 deficiency resulted in a 50% reduction of SMC attachment to gelatin (P<0.01), indicating that SMCs may use MMP-9 as a bridge between the cell surface and matrix. Furthermore, we found that the hyaluronan receptor, CD44, assists in attachment and utilization of MMP-9 by SMCs. Understanding the specific roles of these MMPs, generally thought to be similar, could improve the design of therapeutic interventions aimed at controlling vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551157     DOI: 10.1161/01.ATV.0000100402.69997.C3

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  107 in total

Review 1.  Airway remodelling in asthma: from benchside to clinical practice.

Authors:  Céline Bergeron; Meri K Tulic; Qutayba Hamid
Journal:  Can Respir J       Date:  2010 Jul-Aug       Impact factor: 2.409

Review 2.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 3.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 4.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

5.  Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction.

Authors:  Jiqiu Chen; Ching-Hsuan Tung; Jennifer R Allport; Si Chen; Ralph Weissleder; Paul L Huang
Journal:  Circulation       Date:  2005-04-04       Impact factor: 29.690

Review 6.  Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury.

Authors:  Christopher A Papaharalambus; Kathy K Griendling
Journal:  Trends Cardiovasc Med       Date:  2007-02       Impact factor: 6.677

Review 7.  The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease.

Authors:  Simon W Rabkin
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

8.  Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices.

Authors:  Christopher Franco; Bernard Ho; Diane Mulholland; Guangpei Hou; Muzharul Islam; Katey Donaldson; Michelle Patricia Bendeck
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

9.  Effect of matrix metalloproteinase-9 knockout on vein graft remodelling in mice.

Authors:  Anita C Thomas; Andrew C Newby
Journal:  J Vasc Res       Date:  2009-12-16       Impact factor: 1.934

10.  The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling.

Authors:  Kristopher B Deatrick; Catherine E Luke; Megan A Elfline; Vikram Sood; Joseph Baldwin; Gilbert R Upchurch; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke
Journal:  J Vasc Surg       Date:  2013-03-13       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.